Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy

被引:24
|
作者
Chen, B
Timiryasova, TM
Gridley, DS
Andres, ML
Dutta-Roy, R
Fodor, I
机构
[1] Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Loma Linda, CA 92350 USA
[2] Loma Linda Univ, Sch Med, Dept Microbiol & Mol Genet, Loma Linda, CA 92350 USA
[3] Loma Linda Univ, Sch Med, Dept Radiat Med, Loma Linda, CA 92350 USA
关键词
glioma; IL-2; IL-12; toxicity; vaccinia virus;
D O I
10.1006/cyto.2001.0906
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Single intratumoural treatment of nude mice with a vaccinia virus (VV)-expressing interleukin-1 (IL-2) or IL-12 induced significant tumour growth inhibition associated with clear signs of toxicity. At a low virus dose, only some treated animals showed signs of toxicity. We characterized and compared the activity of NK and B cells and major pro-inflammatory factors (IFN-gamma, TNF-alpha) in treated animals with and without toxicity. One week after treatment animals exhibiting signs of cytokine-related toxicity showed dramatic increases in several measured parameters. High leukocyte and lymphocyte counts in blood and marked increases in NK and CD25(+) cells in both blood and spleen were associated with IL-2-induced toxicity, while IL-12-induced toxicity was related to a great elevation of CD25(+) cells in blood and CD71(+) cells in the spleen. In contrast, immune activation in animals free of toxicity was observed on day 2 after the treatment, which drastically declined by day 7. Thus, immune responses induced by IL-2 and IL-12 therapy appear to play important roles in both tumour inhibition and the accompanying toxicity. Short-term effects induced by IL-2 and IL-12 could be critical for antitumour therapy that prolongs survival and protects from adverse side effects.
引用
收藏
页码:305 / 314
页数:10
相关论文
共 50 条
  • [1] Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model
    Chen, B
    Timiryasova, TM
    Andres, ML
    Kajioka, EH
    Dutta-Roy, R
    Gridley, DS
    Fodor, I
    CANCER GENE THERAPY, 2000, 7 (11) : 1437 - 1447
  • [2] Combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2 and IL-12 in a glioma model
    Fodor, I
    Chen, B
    Timiryasova, TM
    Andres, ML
    Kajioka, EH
    Dutta-Roy, R
    Gridley, DS
    CANCER GENE THERAPY, 2000, 7 (12) : S6 - S6
  • [3] Evaluation of combined vaccinia virus–mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model
    Bing Chen
    Tatyana M Timiryasova
    Melba L Andres
    Eric H Kajioka
    Radha Dutta-Roy
    Daila S Gridley
    Istvan Fodor
    Cancer Gene Therapy, 2000, 7 : 1437 - 1447
  • [4] Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12
    Siapati, KE
    Barker, S
    Kinnon, C
    Michalski, A
    Anderson, R
    Brickell, P
    Thrasher, AJ
    Hart, SL
    BRITISH JOURNAL OF CANCER, 2003, 88 (10) : 1641 - 1648
  • [5] Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12
    K E Siapati
    S Barker
    C Kinnon
    A Michalski
    R Anderson
    P Brickell
    A J Thrasher
    S L Hart
    British Journal of Cancer, 2003, 88 : 1641 - 1648
  • [6] Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
    Barker, S. E.
    Grosse, S. M.
    Siapati, E. K.
    Kritz, A.
    Kinnon, C.
    Thrasher, A. J.
    Hart, S. L.
    BRITISH JOURNAL OF CANCER, 2007, 97 (02) : 210 - 217
  • [7] Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
    S E Barker
    S M Grosse
    E K Siapati
    A Kritz
    C Kinnon
    A J Thrasher
    S L Hart
    British Journal of Cancer, 2007, 97 : 210 - 217
  • [8] Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression
    Agnieszka Masztalerz
    Nico Van Rooijen
    Willem Den Otter
    Linda A. Everse
    Cancer Immunology, Immunotherapy, 2003, 52 : 235 - 242
  • [9] Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression
    Masztalerz, A
    Van Rooijen, N
    Den Otter, W
    Everse, LA
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (04) : 235 - 242
  • [10] Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity
    Kaufman, HL
    Flanagan, K
    Lee, CSD
    Perretta, DJ
    Horig, H
    VACCINE, 2002, 20 (13-14) : 1862 - 1869